XTL Current Deferred Revenue from 2010 to 2024
| XTLB Stock | USD 1.91 0.06 3.24% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 31.5 K | Current Value 29.9 K | Quarterly Volatility 94.2 K |
Check XTL Biopharmaceutica financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XTL Biopharmaceutica's main balance sheet or income statement drivers, such as Other Operating Expenses of 726.8 K, Research Development of 29.4 K or Total Operating Expenses of 726.8 K, as well as many indicators such as Price To Sales Ratio of 0.15, Dividend Yield of 0.0 or PTB Ratio of 2.41. XTL financial statements analysis is a perfect complement when working with XTL Biopharmaceutica Valuation or Volatility modules.
XTL | Current Deferred Revenue |
Latest XTL Biopharmaceutica's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of XTL Biopharmaceuticals Ltd over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. XTL Biopharmaceutica's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in XTL Biopharmaceutica's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
XTL Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 58,695 | |
| Geometric Mean | 40,452 | |
| Coefficient Of Variation | 160.41 | |
| Mean Deviation | 45,374 | |
| Median | 35,000 | |
| Standard Deviation | 94,155 | |
| Sample Variance | 8.9B | |
| Range | 369.1K | |
| R-Value | (0.44) | |
| Mean Square Error | 7.7B | |
| R-Squared | 0.20 | |
| Significance | 0.1 | |
| Slope | (9,302) | |
| Total Sum of Squares | 124.1B |
XTL Current Deferred Revenue History
About XTL Biopharmaceutica Financial Statements
XTL Biopharmaceutica stakeholders use historical fundamental indicators, such as XTL Biopharmaceutica's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although XTL Biopharmaceutica investors may analyze each financial statement separately, they are all interrelated. For example, changes in XTL Biopharmaceutica's assets and liabilities are reflected in the revenues and expenses on XTL Biopharmaceutica's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in XTL Biopharmaceuticals Ltd. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 31.5 K | 29.9 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:Check out the analysis of XTL Biopharmaceutica Correlation against competitors. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share (0.03) | Return On Assets (0.14) | Return On Equity (0.13) |
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.